In an attempt to determine the role of EGFL7 in GBMs, we found that (i) EGFL7 was majorly expressed in glioma blood vessels, (ii) promoted glioma angiogenesis and as a consequence growth, (iii) acted independently of miR‐126/126*, and (iv) EGFL7‐blockage, in particular in combination with VEGF inhibition and temozolomide (TMD), proved to be a useful tool for brain tumor treatment in experimental glioma models. Here, EGFL7 is linked to central nervous system cancer.